Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the company's COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.'

Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science

Novavax, Inc. (NASDAQ: NVAX) shares are advancing yet again Monday on above-average volume, extending the recent momentum the shares have been experiencing. Some of the optimism may be attributed to reports in the Canadian press that the company has quietly submitted an application to Health Canada for beginning a rolling review of NVX-CoV2373, its coronavirus vaccine candidate.

Why Novavax Shares Are Trading Higher Again

An analyst has even higher expectations for the biotech stock after its outstanding COVID-19 vaccine results.

Why Novavax Stock Is Soaring Again Today

Novavax has said that its Covid-19 shot is 89.3% effective, based on interim data from its phase 3 clinical trials conducted in the U.K. [1] The company expects to file for emergency authorization with U.K. regulators in the coming months. While the reported efficacy numbers put the vaccine.

Novavax's Highly Effective Vaccine Could Be A Game Changer

BioNTech SE

Johnson & Johnson

Moderna

Pfizer

Which Is the Best COVID Vaccine Stock: Pfizer, BioNTech, Moderna, Johnson & Johnson, or Novavax?

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update

Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K. The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for Novavax shares.

Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analysts Takes

Novavax, an unlikely vaccine maker, lands another triumph for humankind and NVAX stock looks poised to keep soaring. The post Novavax Vaccine's Phase 3 Win Is Sending NVAX Stock to $350 appeared first on InvestorPlace.

Novavax Vaccine's Phase 3 Win Is Sending NVAX Stock to $350

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.

Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study

The stock price of Novavax, Inc. (NASDAQ: NVAX) is trading up more than 60%. This is why it happened.

NVAX Stock Price Increases Over 60%: Why It Happened

The global case tally for the coronavirus-borne illness COVID-19 was headed toward 102 million on Friday, as health experts were digesting the latest vaccine updates from Novavax Inc. and Johnson & Johnson amid hopes they will soon win emergency authorization and bolster supplies.

Coronavirus Update: Vaccine hopes boosted by data from Novavax and J&J, but fears over new variants remain

Novavax, Inc. (NASDAQ:NVAX) is the latest pharmaceutical stock racing to the Covid-19 vaccine finish line, after late-stage trials showed its candidate is more than 89% effective in protecting against the virus, and nearly as effective against the new strains found in the United Kingdom and South Africa.

NVAX Surges After Analyst Calls Covid-19 Vaccine "Best-in-Class"

Novavax is in the spotlight as a U.K. study showed its Covid-19 vaccine to be 89% effective. As with other biopharma stocks before it, NVAX stock surged on the news.

NVAX Stock: Why Novavax Shares Are Shooting Higher Today

The U.S. biotech has produced an interim assessment of its Phase-3 trial in the U.K., for which I volunteered last year. And it shows the vaccine is 89% effective against the disease.

Dispatches from a Pandemic: The Novavax vaccine is effective. Now I'm seriously hoping that's what I was injected with

The small biotech just reported terrific news for its COVID-19 vaccine candidate.

Look Out, Pfizer and Moderna: Here Comes Novavax

Novavax, Inc (NASDAQ: NVAX) shares rose over 28% in regular trading and the after-hours session on Thursday. What Happened: The Maryland-based vaccine maker said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom.

Why Novavax Shares Surged 28% Today

The shots showed 89% efficacy in a British trial. Against a new virus variant in South Africa, efficacy was just 49%.

Novavax Says Its Vaccine Is 89% Effective in Britain--but Not as Effective Against the South African Variant

Results of a U.K. study suggest that an easy-to-distribute COVID-19 vaccine from Novavax is effective against the new variant.

Coronavirus Vaccine From Novavax Is 89.3% Effective

You'd shoot 30%-plus higher too if you tested as well as the company's vaccine candidate.

Why Novavax Was a Coronavirus Stock Winner After Hours Today

Other vaccines have also proven less effective against a new coronavirus strain discovered in South Africa.

Novavax Covid Vaccine Is Highly Effective Against U.K. Variant But Struggled In South Africa, Data Shows

Novavax on Thursday said its experimental coronavirus vaccine was highly effective at preventing the disease in a UK trial, but disappointing results from a study of the same shot in South Africa raises questions. The vaccine developer said that its shot was 89% effective at preventing symptomatic COVID-19, based on a trial of more than 15,000 patients taking place in the UK. The company published the results in a press release, and said it plans to submit them to a scientific journal for review.

Novavax says its coronavirus vaccine was 89% effective in a UK trial, but it didn't work nearly as well in a second study

Novavax said late Thursday its experimental coronavirus vaccine was nearly 90% effective in a Phase 3 test. The news prodded NVAX stock to surge in after-hours trading.

Novavax Stock Surges After Covid Vaccine Proves Nearly 90% Effective

Novavax Inc. shares jumped more than 20% in after-hours trading Thursday, after the company revealed results of studies that showed its proposed COVID-19 vaccine is nearly 90% effective overall, but much less effective against a new variant.

Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in UK, less against new South African variant

Biotech firm Novavax said Thursday that its coronavirus vaccine was more than 89% effective in protecting against Covid-19.

Novavax says Covid vaccine is more than 89% effective

First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants

News for Novavax Stock (NVAX)